Cohance Lifesciences Schedules Q3 & 9MFY26 Results Conference Call for Feb 12, 2026
Cohance Lifesciences will host an investor and analyst conference call on February 12, 2026, at 6:15 PM IST to discuss its Q3 & 9MFY26 Un-audited Financial Results. The call will include a management discussion and Q&A session. Dial-in details and pre-registration information are provided.
This is a standard procedural announcement regarding a future investor call. It does not contain any new financial information or strategic decisions that would significantly impact the company's stock or operations at this stage.
The announcement is a routine schedule for an upcoming investor call to discuss financial results. It does not contain any information about the results themselves, nor does it indicate any particularly positive or negative developments.
Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) has announced the schedule for a conference call for investors and analysts to discuss the Un-audited Financial Results for the third quarter and nine months of the fiscal year 2026.
The conference call is scheduled to take place on Thursday, February 12, 2026, at 06:15 p.m. IST. The senior management of the company will participate in the call, which will commence with a management discussion on the Q3 & 9MFY26 results to be declared earlier in the day, followed by an interactive Question & Answer session.
Details for the conference call include primary dial-in numbers (+91 22 6280 1141 / +91 22 7115 8042) and international toll-free numbers for Singapore, Hong Kong, USA, and UK. Participants are encouraged to pre-register via a provided link to receive dial-in numbers, a passcode, and a PIN via email. Attendees are advised to dial in 5-10 minutes prior to the scheduled start time. For further information, investors can contact Kundan Kumar Jha (Company Secretary) at Cohance Lifesciences Limited, or Cyndrella Carvalho (Head - Investor Relations), or Gavin Desa / Rishab Barar at CDR India.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.